Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-811X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors ; volume:18 ; number:1 ; day:5 ; month:11 ; year:2020 ; pages:1-7 ; date:12.2020
Cell communication and signaling ; 18, Heft 1 (5.11.2020), 1-7, 12.2020
- Creator
-
McFall, Thomas
Schomburg, Noah K.
Rossman, Kent L.
Stites, Edward C.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12964-020-00645-3
- URN
-
urn:nbn:de:101:1-2020121818345655453658
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- McFall, Thomas
- Schomburg, Noah K.
- Rossman, Kent L.
- Stites, Edward C.
- SpringerLink (Online service)
Other Objects (12)
AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
Colorectal cancer with KRAS mutation
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells
The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer
BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer
Predictive role of [18F]FDG PET-CT radiomic parameters for KRAS/BRAF/EGFR mutations in metastatic colorectal cancer patients
ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer
398 - The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies [Poster abstract]
Untersuchung des EGFR-Signalwegs und des KRAS-Mutationsstatus an Kolonkarzinomen mittels Gewebemikroarray
Prognostische Bedeutung der Mutationslast von EGFR und KRAS in Adenokarzinomen der Lunge
AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
Colorectal cancer with KRAS mutation
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells
The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer
BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer
Predictive role of [18F]FDG PET-CT radiomic parameters for KRAS/BRAF/EGFR mutations in metastatic colorectal cancer patients
ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer
398 - The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies [Poster abstract]
Untersuchung des EGFR-Signalwegs und des KRAS-Mutationsstatus an Kolonkarzinomen mittels Gewebemikroarray
Prognostische Bedeutung der Mutationslast von EGFR und KRAS in Adenokarzinomen der Lunge
AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
Colorectal cancer with KRAS mutation
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells
The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer
BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer
Predictive role of [18F]FDG PET-CT radiomic parameters for KRAS/BRAF/EGFR mutations in metastatic colorectal cancer patients
ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer
398 - The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies [Poster abstract]
Untersuchung des EGFR-Signalwegs und des KRAS-Mutationsstatus an Kolonkarzinomen mittels Gewebemikroarray